FDA Broke Catalyst&39;s Orphan Exclusivity Due To Pricing Not Clinical Concerns Firm Claims
FDA Broke Catalyst's Orphan Exclusivity Due To Pricing, Not Clinical, Concerns, Firm Claims
17:15 EST 13 Feb 2020 |
SCRIP
Suit against agency reveals internal discussions to approve Jacobus' Ruzurgi despite Catalyst's orphan exclusivity for the same drug; Sen. Bernie...
More From BioPortfolio on "FDA Broke Catalyst's Orphan Exclusivity Due To Pricing, Not Clinical, Concerns, Firm Claims"